Compare SAIC & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SAIC | PTCT |
|---|---|---|
| Founded | 1969 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 5.0B |
| IPO Year | 2013 | 2006 |
| Metric | SAIC | PTCT |
|---|---|---|
| Price | $150.74 | $63.60 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 10 | 15 |
| Target Price | ★ $132.56 | $100.47 |
| AVG Volume (30 Days) | 362.9K | ★ 1.0M |
| Earning Date | 12-03-2026 | 10-29-2026 |
| Dividend Yield | ★ 0.98% | N/A |
| EPS Growth | 7.39 | ★ 264.48 |
| EPS | ★ 5.00 | 0.34 |
| Revenue | ★ $7,262,000,000.00 | $264,734,000.00 |
| Revenue This Year | $0.49 | N/A |
| Revenue Next Year | $1.38 | $8.29 |
| P/E Ratio | ★ $30.19 | $187.03 |
| Revenue Growth | N/A | ★ 36.19 |
| 52 Week Low | $81.08 | $58.80 |
| 52 Week High | $155.11 | $90.87 |
| Indicator | SAIC | PTCT |
|---|---|---|
| Relative Strength Index (RSI) | 62.07 | 47.73 |
| Support Level | $122.58 | $60.16 |
| Resistance Level | $155.11 | $63.74 |
| Average True Range (ATR) | 5.36 | 2.69 |
| MACD | -0.36 | 0.09 |
| Stochastic Oscillator | 66.71 | 36.62 |
Science Applications International Corp provides technical, engineering, and enterprise IT services mainly to the U.S. government. Specifically, it offers end-to-end solutions spanning the design, development, integration, deployment, management, operations, sustainment, and security of the customer's entire IT infrastructure. The company has two reportable segments, which include Defense and Intelligence and the Civilian segment. Maximum revenue is generated from its Defense and Intelligence segment, which provides a diverse portfolio of national security solutions to the DoW and the Intelligence Community of the United States Government. The Civilian segment provides solutions to the civilian markets, encompassing federal, state, and local governments.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.